Pfizer Q3 Earnings Beat Estimates, Sales Decline as COVID Demand Cools

Key Takeaways Pfizer's Q3 adjusted EPS of $0.87 beat estimates but fell 18% year over year.Revenues dropped 6% to$ 16.7B, hurt by lower Comirnaty and Paxlovid sales.Pfizer reaffirmed revenue outlook and lifted 2025 EPS guidance to $3.00-$ 3.15.Pfizer (PFE) reported third-quarter 2025 adjusted earnings per share of 87 cents, which comprehensively beat the Zacks Consensus Estimate of 66 cents per share. Earnings declined 18% year over year.Adjusted EPS includes an acquired in-process R&D charge of 20 cents per ...